Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study

ABSTRACT:

SUBMITTER: Shen N 

PROVIDER: S-EPMC12352177 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature